Course curriculum

  • 1

    AMSL Sponsored breakfast Session

    • PART 1: Closing the Gap: Translating CGM Evidence into Routine Type 2 Diabetes Care
  • 2

    Session 1: Diabetes Advancements & Technology

    • From Biomarkers to Intervention: Using C-peptide and CGM in Early-Stage Type 1 Diabetes

    • Driving the Diabetes Revolution with CKM: What HCPs Need to Know About this New Technology

    • Start Strong with AID: Rethinking Diabetes Care

    • Automated insulin delivery in diabetes: the latest published evidence and real-world application

    • Expanding Access to Automated Insulin Delivery: Real World Outcomes and Lessons from the FREEDOM Study

  • 3

    Session 2: Therapeutics & Technology in Action

    • What's new in insulin therapy

    • With more CGMs on the market, what checks and balances do we need?

    • Equity and Bias in Diabetes AID Technology

    • Technology Use in Residential Aged Care Settings

    • Therapeutics & Technology in Action - Q&A Panel Discussion
  • 4

    Session 3: Access to diabetes tech in Australia - what needs to be done to prevent inequity and what can we learn from other countries?

    • Part 1: Panel Discusssion - Access to diabetes tech in Australia - what needs to be done to prevent inequity and what can we learn from other countries?

    • Part 2: Panel Discusssion - Access to diabetes tech in Australia - what needs to be done to prevent inequity and what can we learn from other countries?
  • 5

    Session 4: AI & Clinical Decision Support in Diabetes Care

    • AI & Clinical Decision Support in Diabetes Care

    • Digital twins - what are they and how do we use them in clinical care

    • Travelling, driving and employment with diabetes technology

    • Impaired Executive Function and Use of Diabetes Technologies
  • 6

    Session 5: Hot off the press and out of the research lab

    • Revisiting and redefining hypoglycaemia in the era of diabetes technologies in children with type 1 diabetes

    • Novel gene therapy for adults with type 1 diabetes? The RESTORE study

    • From CGM Data to Predictive Risk Models: Insights into Diabetes and Cardiovascular Outcomes

    • The Missing Complication: Integrating Liver Screening into Diabetes Care
  • 7

    ADATS Closing

    • FEEDBACK SURVEY